What is SVRA stock price today?

SVRA (Savara Inc) stock is trading at $5.78 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SVRA stock going up or down today?

SVRA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SVRA stock now?

The decision to buy SVRA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SVRA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SVRA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SVRA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if SVRA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is SVRA's P/E ratio?

P/E ratio data for SVRA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is SVRA's market cap?

SVRA (Savara Inc) has a market capitalization of $1.18 billion, making it a small-cap stock.

What is SVRA's price to book ratio?

SVRA trades at a price-to-book (P/B) ratio of 5.82, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SVRA pay dividends?

SVRA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SVRA's dividend yield?

SVRA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SVRA stock a good long-term investment?

SVRA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SVRA's revenue growth rate?

Revenue growth data for SVRA is available on our dashboard with detailed financial statement analysis.

Profitability metrics for SVRA are available on our dashboard with complete income statement analysis.

What are the risks of investing in SVRA?

Key risks for SVRA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SVRA compare to its competitors?

Compare SVRA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SVRA's performance and positioning.

What is SVRA's stock price target for 2026?

Our AI model provides price targets for SVRA based on fundamental analysis: Bull case $7.51 (+30%), Base case $6.65 (+15%), Bear case $5.20 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SVRA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SVRA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SVRA's next earnings report?

SVRA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SVRA - Savara Inc

NYSE * Health Care * Biotechnology

$5.78

+$0.14 (+2.48%)

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

SVRA Key Statistics

Market Cap

$1.18B

P/B Ratio

5.82

EPS

$-0.53

Employees

How SVRA Compares to Peers

SVRA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SVRA(This stock)	$1.18B	N/A	0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Savara Inc Company Information

Headquarters: Texas; U.S.A
Website: www.savarapharma.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 19, 2026 at 6:38 PM EDT

Ready to invest in SVRA?

Commission-free trading available. Affiliate links.

SVRA Lician Score

5% confidence

4.0/10

Neutral

SVRA has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates SVRAacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

SVRA Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for SVRA

Dashboard

Enter a ticker to analyze